Congenital heart disease (CHD) is the most prevalent congenital anomaly in newborn
babies. Cardiac malformations have been induced in different animal model experiments, by …

For more than a decade, stem cell therapy has been the focus of intensive efforts for the
treatment of adult heart disease, and now has promise for treating the pediatric population …

This article reports on the evolving field of stem cell therapy and its impact on the
management of cardiac pathology, in particular congenital heart disease. To date, stem cell …

Dramatic evolution in medical and catheter interventions and complex surgeries to treat
children with congenital heart disease (CHD) has led to a growing number of patients with a …

This review article reports on the new field of stem cell therapy and tissue engineering and
its potential on the management of congenital heart disease. To date, stem cell therapy has …

Background: Congenital heart disease (CHD) constitutes the most prevalent and
heterogeneous group of congenital anomalies. Although surgery remains the gold standard …

Heart failure is a leading cause of death worldwide. Current therapies only delay
progression of the cardiac disease or replace the diseased heart with cardiac …

Research on stem cells has been rapidly growing with impressive breakthroughs. Although
merely a few of the laboratory researches have successfully transited to the clinical trial …

Congenital heart disease occurs in 1% of liveborn infants, making it the most common birth
defect worldwide. Many of these children develop heart failure. In addition, both genetic and …

Background Congenital heart disease (CHD) continues to be among the most common birth
defects, affecting an estimated 40 000 births annually in the United States. The most …